美罗培南联合连续性肾脏替代治疗脓毒症急性肾损伤的效果及对肾功能恢复的影响

doi:10.3760/cma.j.cn441417-20241030-09020

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (9): 1511-1515.DOI: 10.3760/cma.j.cn441417-20241030-09020

美罗培南联合连续性肾脏替代治疗脓毒症急性肾损伤的效果及对肾功能恢复的影响

郝鑫¹ 郭威² 谭丹丹³ 郭金燕¹ 马宁¹ 兰玉怀¹

¹黑龙江省医院重症医学科，哈尔滨 150036；²哈尔滨市第五医院重症医学科，哈尔滨 150036；³黑龙江省医院护理部，哈尔滨 150036

收稿日期:2024-10-30 出版日期:2025-05-01 发布日期:2025-05-20
通讯作者: 郝鑫，Email：haoxin202409@163.com
基金资助:
2023年度黑龙江省卫生健康委科技计划（20231717010422）

Efficacy of meropenem combined with continuous renal replacement therapy in the treatment of sepsis-associated acute kidney injury and its impact on renal function recovery

Hao Xin¹, Guo Wei², Tan Dandan³, Guo Jinyan¹, Ma Ning¹, Lan Yuhuai¹

¹Department of Critical Care Medicine, Heilongjiang Provincial Hospital, Harbin 150036, China; ²Department of Critical Care Medicine, The Fifth Hospital of Harbin City, Harbin 150036, China; ³Department of Nursing, Heilongjiang Provincial Hospital, Harbin 150036, China

Received:2024-10-30 Online:2025-05-01 Published:2025-05-20
Contact: Hao Xin, Email: haoxin202409@163.com
Supported by:
2023 Heilongjiang Provincial Health Commission Science and Technology Plan (20231717010422)

摘要/Abstract

摘要： 目的　探究美罗培南联合连续性肾脏替代治疗（CRRT）脓毒症急性肾损伤（S-AKI）的效果及对肾功能恢复的影响。方法　选取2023年6月至2024年5月黑龙江省医院收治的60例S-AKI患者作为研究对象。采用随机数字表法，将患者分为观察组与对照组，各30例。对照组男12例，女18例；年龄（38.50±2.75）岁；急性肾损伤分期：Ⅰ期17例，Ⅱ期7例，Ⅲ期6例。观察组男14例，女16例；年龄（38.17±2.63）岁；急性肾损伤分期：Ⅰ期15例，Ⅱ期8例，Ⅲ期7例。对照组采用CRRT，观察组采用美罗培南联合CRRT。比较两组治疗效果［重症监护病房（ICU）住院时间、尿量恢复时间及心血管事件］、生存情况；治疗前和治疗3 d后感染性指标［白细胞计数（WBC）、中性粒细胞比率（NEUR）及降钙素原（PCT）］、炎症因子［白细胞介素（IL）-6、IL-1β及肿瘤坏死因子-α（TNF-α）］和肾功能［血尿素氮（BUN）、尿蛋白及肌酐］。采用独立样本t检验、配对t检验和χ2检验进行统计学分析。结果　观察组ICU住院时间、尿量恢复时间均短于对照组［（8.67±1.49）d比（12.23±3.67）d、（7.63±4.48）d比（11.27±8.28）d］，心血管事件总发生率低于对照组［13.33%（4/30）比40.00%（12/30）］（均P<0.05）。治疗3 d后，观察组WBC、NEUR及PCT水平均低于对照组［（8.91±3.08）×109/L比（11.57±5.59）×109/L、（71.10±2.30）%比（76.54±3.13）%、（0.39±0.09）μg/L比（0.45±0.09）μg/L］（均P<0.05）；观察组IL-6、IL-1β及TNF-α水平均低于对照组［（87.58±9.07）ng/L比（185.32±23.23）ng/L、（14.58±3.26）μg/L比（24.06±3.61）μg/L、（45.37±8.29）ng/L比（74.09±9.27）ng/L］（均P<0.05）；观察组BUN、尿蛋白及肌酐水平均低于对照组［（7.12±0.93）mmol/L比（9.71±1.13）mmol/L、（6.18±1.18）mg/24 h比（10.97±2.35）mg/24 h、（49.51±2.18）μmol/L比（57.05±5.28）μmol/L］（均P<0.05）。随访28 d后，观察组存活率高于对照组［93.33%（28/30）比73.33%（22/30）］（P<0.05）。结论　美罗培南联合CRRT可减少S-AKI患者ICU住院时间、尿量恢复时间，降低心血管事件发生率和感染性指标、炎症因子水平，有助于肾功能恢复，提高存活率。

关键词: 脓毒症急性肾损伤, 美罗培南, 连续性肾脏替代治疗, 疗效, 肾功能

Abstract:

Objective　To investigate the efficacy of meropenem combined with continuous renal replacement therapy (CRRT) in the treatment of sepsis-associated acute kidney injury (S-AKI) and its impact on renal function recovery. Methods　A total of 60 patients with S-AKI admitted to Heilongjiang Provincial Hospital from June 2023 to May 2024 were selected as the study subjects. Using a random number table, patients were divided into an observation group and a control group, with 30 patients in each group. There were 12 males and 18 females in the control group, aged (38.50±2.75) years, acute kidney injury staging: stage Ⅰ (17 cases), stage Ⅱ (7 cases), and stage Ⅲ (6 cases). There were 14 males and 16 females in the observation group, aged (38.17±2.63) years, acute kidney injury staging: stage Ⅰ (15 cases), stage Ⅱ (8 cases), and stage Ⅲ (7 cases). The control group received CRRT, while the observation group received meropenem combined with CRRT. Therapeutic outcomes [intensive care unit (ICU) stay duration, urine output recovery time, and cardiovascular events], survival rates; infectious indicators [white blood cell count (WBC), neutrophil ratio (NEUR), and procalcitonin (PCT)], inflammatory factors [interleukin (IL)-6, IL-1β, and tumor necrosis factor-α (TNF-α)], and renal function indicators [blood urea nitrogen (BUN), urinary protein, and creatinine] were compared before and 3 d after treatment. Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　The ICU hospitalization time and the time for urine output recovery in the observation group were shorter than those in the control group [(8.67±1.49) d vs. (12.23±3.67) d, (7.63±4.48) d vs. (11.27±8.28) d], and the total incidence rate of cardiovascular events was lower than that of the control group [13.33% (4/30) vs. 40.00% (12/30)] (all P<0.05). After 3 d of treatment, the levels of WBC, NEUR and PCT in the observation group were lower than those in the control group [(8.91±3.08)×10⁹/L vs. (11.57±5.59)×10⁹/L, (71.10±2.30)% vs. (76.54±3.13)%, (0.39±0.09) μg/L vs. (0.45±0.09) μg/L] (all P<0.05); the levels of IL-6, IL-1β and TNF-α in the observation group were lower than those in the control group [(87.58±9.07) ng/L vs. (185.32±23.23) ng/L, (14.58±3.26) μg/L vs. (24.06±3.61) μg/L, (45.37±8.29) ng/L vs. (74.09±9.27) ng/L] (all P<0.05); the levels of BUN, urine protein and creatinine in the observation group were lower than those in the control group [(7.12±0.93) mmol/L vs. (9.71±1.13) mmol/L, (6.18±1.18) mg/24 h vs. (10.97±2.35) mg/24 h, (49.51±2.18) μmol/L vs. (57.05±5.28) μmol/L] (all P<0.05). After 28 d of follow-up, the survival rate in the observation group was higher than that in the control group [93.33% (28/30) vs. 73.33% (22/30)] (P<0.05). Conclusion　Meropenem combined with CRRT can reduce ICU stay duration, urine output recovery time, and the incidence of cardiovascular events in patients with S-AKI. It also lowers infectious indicators and inflammatory factor levels, aids in renal function recovery, and improves survival rates.

Key words: Sepsis-associated acute kidney injury, , Meropenem, , Continuous renal replacement therapy, , Therapeutic efficacy, , Renal function

郝鑫郭威谭丹丹郭金燕马宁兰玉怀.

美罗培南联合连续性肾脏替代治疗脓毒症急性肾损伤的效果及对肾功能恢复的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1511-1515.

Hao Xin, Guo Wei, Tan Dandan, Guo Jinyan, Ma Ning, Lan Yuhuai.

Efficacy of meropenem combined with continuous renal replacement therapy in the treatment of sepsis-associated acute kidney injury and its impact on renal function recovery [J]. International Medicine and Health Guidance News, 2025, 31(9): 1511-1515.

参考文献

[1]王楠,王美平,姜利,等.脓毒症相关性急性肾损伤发生时间与临床结局的关系[J].中华医学杂志,2024,104(21):1972-1978.DOI:10.3760/cma.j.cn112137-20231030- 00940.

[2]李晓寒,朱长举,兰超,等.脓毒症相关急性肾损伤死亡预测模型的构建[J].中华危重病急救医学,2024,36(4):381-386.DOI:10.3760/cma.j.cn121430-20240130-00098.

[3]李静,孟润祺,郭鲁恒,等.在线动态列线图可视化分析脓毒症患者发生急性肾损伤的预测模型:开发与验证应用研究[J].中华危重病急救医学,2024,36(10):1069-1074.DOI:10.3760/cma.j.cn121430-20240102-00003.

[4]王跃胜,周晓莎,陈剑平,等.脓毒症伴急性肾损伤患者48 h内有创通气风险的预测模型的建立与验证[J].中华急诊医学杂志,2024,33(4):549-557.DOI:10.3760/cma.j.issn. 1671-0282.2024.04.016.

[5]笪伟,朱甜甜,王晓波,等.VExUS评分在脓毒症合并急性肾损伤患者中的应用价值[J].中华急诊医学杂志,2024,33(3):312-316.DOI:10.3760/cma.j.issn.1671-0282.2024.03.009.

[6]Manrique-Caballero CL, Del Rio-Pertuz G, Gomez H. Sepsis-associated acute kidney injury[J]. Crit Care Clin, 2021, 37(2):279-301. DOI: 10.1016/j.ccc.2020.11.010.

[7]盛伟,边文亚,张小凯.SLED联合HP与CRRT联合HP治疗脓毒症急性肾损伤临床疗效对比研究[J].中国中西医结合肾病杂志,2023,24(2):142-144.DOI:10.3969/j.issn. 1009-587X.2023.02.013.

[8]孙维维,黄晓英,王亚东.HELENICC评分预测脓毒症相关急性肾损伤行持续肾脏替代治疗患者早期病死率的价值[J].实用临床医药杂志,2023,27(15):29-34.DOI:10.7619/jcmp.20231689.

[9]温小龙,邢柏.万古霉素单药与联合β-内酰胺类药物对脓毒症患者急性肾损伤发生和预后的影响[J].天津医药,2021,49(1):36-41.DOI:10.11958/20201821.

[10]李东风,李雅琳,孙振康,等.延长美罗培南输注时间对老年脓毒症患者预后的影响[J].实用临床医药杂志,2023,27(15):115-119.DOI:10.7619/jcmp.20232026.

[11]Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11):1181-1247. DOI: 10.1007/s00134-021- 06506-y.

[12]郑因碧,邵义明,黎焯基,等.右美托咪定对脓毒症急性肾损伤患者的肾功能影响的队列研究[J].实用医学杂志,2024,40(10):1423-1428.DOI:10.3969/j.issn.1006-5725. 2024.10.016.

[13]李志华,于湘友,王毅,等.血清iFABP和DAO对脓毒症及脓毒症肠道损伤的诊断及预后评判价值[J].海南医科大学学报,2025,31(4):270-276.DOI:10.13210/j.cnki.jhmu. 20240912.002.

[14]杜罕,汪之玉,祝巍.乌司他丁联合CRRT对脓毒症急性肾损伤患者肾功能及HMGB1、KIM-1、PCT的影响[J].中国中西医结合肾病杂志,2024,25(5):424-426.DOI:10.3969/j.issn.1009-587X.2024.05.013.

[15]岳筱,李志芳,王蕾,等.脓毒症相关性急性肾损伤患者3个月死亡风险列线图预测模型的建立与评价[J].中华危重病急救医学,2024,36(5):465-470.DOI:10.3760/cma.j.cn121430-20231218-01091.

[16]平泽,张建军,王金荣,等.不同剂量美罗培南治疗脓毒症休克的临床效果比较[J].中国药房,2024,35(13):1624-1627.DOI:10.6039/j.issn.1001-0408.2024.13.14.

[17]雷忠,张开龙,殷燕.连续性肾替代治疗脓毒症并发急性肾损伤患者疗效及其对血清炎症因子影响[J].中国中西医结合肾病杂志,2021,22(9):823-824.DOI:10.3969/j.issn.1009-587X.2021.09.023.

[18]梅沁,蒋卫杰.前列地尔联合CRRT治疗脓毒症合并急性肾损伤的疗效及对患者血清miR-155、miR-233水平的影响[J].海南医学,2023,34(6):774-777.DOI:10.3969/j.issn. 1003-6350.2023.06.003.

[19]付海英,黄马玉.延长美罗培南输液时间治疗脓毒症休克合并急性肾功能不全患者的临床效果[J].中国急救复苏与灾害医学杂志,2020,15(9):1081-1084.DOI:10.3969/j.issn.1673-6966.2020.09.020.

[20]王翔,张志敏,李建国,等.CRRT与IHD治疗对脓毒症合并急性肾损伤患者尿IGFBP-7、NGAL及TIMP-2水平影响的比较[J].临床肾脏病杂志,2022,22(2):94-99.DOI:10.3969/j.issn.1671-2390.2022.02.002.

[21]续茜桥,杨春静,时正媛.重症患者应用万古霉素联合不同β-内酰胺类抗菌药物治疗的急性肾损伤风险比较[J].中南药学,2021,19(12):2699-2703.DOI:10.7539/j.issn. 1672-2981.2021.12.043.

[22]周圆,杨焕,胡闪闪.灯盏花素联合连续性肾脏替代治疗对脓毒症急性肾损伤的疗效及肾功能恢复的影响[J].临床和实验医学杂志,2022,21(22):2395-2399.DOI:10.3969/j.issn.1671-4695.2022.22.012.

[23]Wu S, Xu T, Wu C, et al. Continuous renal replacement therapy in sepsis-associated acute kidney injury: effects on inflammatory mediators and coagulation function[J]. Asian J Surg, 2021, 44(10):1254-1259. DOI: 10.1016/j.asjsur.2021.02.004.

[24]朱明洋.床旁CRRT联合俯卧位通气在重症ARDS患者中的疗效分析[J].国际医药卫生导报,2023,29(21):3061-3065.DOI:10.3760/cma.j.issn.1007-1245.2023.21.016.

[25]闻超,刘锋,王敏.万古霉素联合亚胺培南西司他丁钠或美罗培南抗感染治疗的急性肾损伤发生率的回顾性分析[J].中国医院药学杂志,2024,44(4):447-450.DOI:10.13286/j.1001-5213.2024.04.13.

[26]郑金花,韦泽丰,顾申红.不同时机CRRT治疗脓毒症急性肾损伤疗效及对血清炎性因子和肾功能及凝血功能的影响[J].热带医学杂志,2023,23(9):1276-1280.DOI:10.3969/j.issn.1672-3619.2023.09.019.

美罗培南联合连续性肾脏替代治疗脓毒症急性肾损伤的效果及对肾功能恢复的影响

Efficacy of meropenem combined with continuous renal replacement therapy in the treatment of sepsis-associated acute kidney injury and its impact on renal function recovery

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贺宇凡邹素文马秋萍欧阳春艳. 超声评价内托生肌法治疗溃后期肉芽肿性乳腺炎的疗效 [J]. 国际医药卫生导报, 2025, 31(8): 1240-1243.
[2]	侯曦丁琪申晓稚杨丹李许涛. 通窍涤痰汤联合针刺治疗缺血性脑卒中急性期患者的临床研究 [J]. 国际医药卫生导报, 2025, 31(8): 1302-1306.
[3]	宋琴琴宋瑞邵娣. 调神舒筋针刺疗法联合肌电生物反馈对中风后踝关节背屈功能障碍的临床疗效 [J]. 国际医药卫生导报, 2025, 31(7): 1074-1078.
[4]	张婷婷牛晓庆李娟李锐宋佳. 超声引导针刀联合秦息痛治疗类风湿性肩关节炎的临床疗效 [J]. 国际医药卫生导报, 2025, 31(7): 1108-1113.
[5]	任羽贺爱军葛繁梅. FAB-M2亚型成人急性髓系白血病患者LPCAT1、CRP、PLT表达水平与临床疗效的相关性分析 [J]. 国际医药卫生导报, 2025, 31(7): 1183-1189.
[6]	王纪科刘锦波. 钬激光与铥激光剜除术治疗良性前列腺增生疗效及安全性的meta分析 [J]. 国际医药卫生导报, 2025, 31(6): 930-939.
[7]	思雅芳刘瑜瑜曹丽. 不同剂量利妥昔单抗治疗特发性膜性肾病的效果及复发影响因素分析 [J]. 国际医药卫生导报, 2025, 31(5): 723-728.
[8]	权皎洁王小玲陈惠娟. 高通量血液透析联合血液透析滤过治疗终末期肾病的效果 [J]. 国际医药卫生导报, 2025, 31(5): 729-733.
[9]	郭桂军刘佛林. 新辅助治疗联合根治性膀胱切除术治疗肌层浸润性膀胱癌的效果 [J]. 国际医药卫生导报, 2025, 31(5): 742-745.
[10]	张鹏娟宁芳卫张中冕范林鹏. 肺叶定量CT参数和HCAR水平与慢性阻塞性肺疾病患者病情程度及疗效的相关性 [J]. 国际医药卫生导报, 2025, 31(5): 779-783.
[11]	吴成琳王绍霞任乐豪. 胸腺肽α1联合比阿培南治疗重症肺炎患者的疗效 [J]. 国际医药卫生导报, 2025, 31(5): 784-787.
[12]	宋群莉关微陈瑶莉. 信迪利单抗联合沙利度胺治疗中晚期食管癌的临床研究 [J]. 国际医药卫生导报, 2025, 31(5): 806-810.
[13]	鲁小庆郭亚平边静赵东艳景煊峰赵亚峰. 加味补阳还五汤联合西药治疗特发性膜性肾病患者的效果 [J]. 国际医药卫生导报, 2025, 31(4): 573-577.
[14]	高好好李朋菊宋虎杰. 依达拉奉联合醒脑静注射液对蛛网膜下腔出血患者神经功能的临床效果 [J]. 国际医药卫生导报, 2025, 31(4): 608-612.
[15]	钟意敏李文芳黄焕容郑洁如冼海燕. 背部低频电刺激配合如意金黄散和手法按摩治疗哺乳期急性乳腺炎患者的疗效观察 [J]. 国际医药卫生导报, 2025, 31(4): 618-622.